Literature DB >> 24749658

First report of ipilimumab-induced Grover disease.

J Munoz1, B Guillot, C Girard, O Dereure, A Du-Thanh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24749658     DOI： 10.1111/bjd.13058

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  9 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 2.  Skin Manifestation Induced by Immune Checkpoint Inhibitors.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-05-10

Review 3.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

4.  Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.

Authors:  Viktor H Koelzer; Tobias Buser; Niels Willi; Sacha I Rothschild; Andreas Wicki; Peter Schiller; Gieri Cathomas; Alfred Zippelius; Kirsten D Mertz
Journal:  J Immunother Cancer       Date:  2016-08-16       Impact factor: 13.751

5.  A Case of Extensive Grover's Disease in a Patient with a History of Multiple Non-Melanoma Skin Cancers.

Authors:  Mareike Kotzerke; Fouad Mitri; Alexander Enk; Ferdinand Toberer; Holger Haenssle
Journal:  Case Rep Dermatol       Date:  2021-12-07

6.  "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.

Authors:  Pietro Sollena; Simone Cappilli; Francesco Federico; Giovanni Schinzari; Giampaolo Tortora; Ketty Peris
Journal:  Hum Vaccin Immunother       Date:  2021-03-24       Impact factor: 4.526

Review 7.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

8.  A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Authors:  Marc Uemura; Faisal Fa'ak; Cara Haymaker; Natalie McQuail; Elizabeth Sirmans; Courtney W Hudgens; Lydia Barbara; Chantale Bernatchez; Jonathan L Curry; Patrick Hwu; Michael T Tetzlaff; Adi Diab
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

9.  Can't handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab.

Authors:  Eva Shelton; Coley Doolittle; Michi M Shinohara; John A Thompson; Ata S Moshiri
Journal:  JAAD Case Rep       Date:  2022-02-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.